BioStem Technologies Reports Record First Quarter Revenue of $41.9 Million
– Company Achieves Record-Breaking First Quarter Results for 2024, Marking the Launch of BioStem 2.0 –
– Company Reports First Quarter EBITDA of $4.9 Million –
– Project Continued Growth from Sales of AmnioWrap2® –
– Financial Results Conference Call and Webcast on Tuesday May 14, 2024 at 4:30 pm EDT –
Related news for (BSEM)
- BioStem Technologies Reports Record Second Quarter 2024 Revenue of $74.5 Million
- BioStem Technologies to Report Second Quarter 2024 Financial Results on Monday, August 12, 2024
- BioStem Receives Institutional Review Board (IRB) Approval to Advance a Clinical Study Evaluating AmnioWrap2™ in Diabetic Foot Ulcers
- BioStem Technologies Reports Breakthrough Results with AmnioWrap2® in Retrospective Wound Care Study
- BioStem Technologies to Sponsor MRO Better Half Dash